4//SEC Filing
CARNEY LLOYD 4
Accession 0001209191-23-005717
CIK 0000875320other
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 4:45 PM ET
Size
8.7 KB
Accession
0001209191-23-005717
Insider Transaction Report
Form 4
CARNEY LLOYD
Director
Transactions
- Sale
Common Stock
2023-01-30$320.70/sh−1,000$320,700→ 4,474 total - Sale
Common Stock
2023-01-30$320.08/sh−1,376$440,430→ 5,474 total - Sale
Common Stock
2023-01-30$321.84/sh−324$104,276→ 4,150 total
Footnotes (5)
- [F1]Transaction made pursuant to Mr. Carney's company approved trading plan under Rule 10b5-1.
- [F2]Mr. Carney undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F3]Open market sales reported on this line occurred at a weighted average price of $320.08 (range $319.40 to $320.38).
- [F4]Open market sales reported on this line occurred at a weighted average price of $320.70 (range $320.43 to $321.31).
- [F5]Open market sales reported on this line occurred at a weighted average price of $321.84 (range $321.54 to $322.23).
Documents
Issuer
VERTEX PHARMACEUTICALS INC / MA
CIK 0000875320
Entity typeother
Related Parties
1- filerCIK 0001204424
Filing Metadata
- Form type
- 4
- Filed
- Jan 30, 7:00 PM ET
- Accepted
- Jan 31, 4:45 PM ET
- Size
- 8.7 KB